Pleurodynia Treatment

Pleurodynia Treatment

The pleurodynia treatment market is expected to register a CAGR of approx. 5% over the period of 2023-2030. Pleurodynia, also known as Bornholm disease, is a viral infection that affects the intercostal muscles, which are the muscles between the ribs. It is characterized by sudden-onset severe chest pain that can be quite intense and may also cause fever and other flu-like symptoms. Pleurodynia is commonly caused by enteroviruses, such as Coxsackieviruses. The growing demand for pleurodynia treatments can be attributed to the increase in the reliance of people on painkillers around the globe. Furthermore, the pleurodynia treatment market is anticipated to grow on account of Increased awareness and improved diagnostic capabilities could lead to more accurate and timely diagnoses of pleurodynia. Moreover, Advances in medical technology and innovations in drug delivery systems or diagnostic tools may facilitate the development and delivery of more effective and targeted treatments for pleurodynia has led to a growing demand for pleurodynia treatments. For instance, in 2021, Novartis, a leading global pharmaceutical company, announced promising results in its research for antiviral therapies. The company's commitment to developing novel antiviral drugs could pave the way for potential treatments for various viral infections, including pleurodynia. However, some of the restraints in the market including the high development costs and variable disease severity are impeding the growth of this market all over the world.

• Based on the diagnosis, the market is segmented into blood test, culture test, and X-ray. Among them, the PVDF segment captured a significant share of the market in 2021. Advancements in blood test technologies and the identification of specific biomarkers associated with pleurodynia may enhance the accuracy of diagnosing the condition. This can lead to more efficient and precise diagnosis, facilitating timely treatment.
• Based on the treatment, the market is bifurcated into analgesics or painkillers and immunoglobulin. Among them, the analgesics or painkillers segment is expected to grow at a higher CAGR in the market. Pleurodynia is characterized by severe chest pain that can be debilitating for patients. Analgesics or painkillers are commonly used to provide symptomatic relief and alleviate pain, making them an essential component of the treatment regimen for pleurodynia.
• Based on the mode of administration, the market is bifurcated into oral and injections or infusion. Among them, the oral segment is expected to grow at a higher CAGR in the market. Oral medications offer a convenient and non-invasive way of administering treatments. Patients may prefer oral drugs over other forms of treatment, such as injections or intravenous therapies, as they are easier to take and do not require medical supervision.
• Based on the end-user, the pleurodynia treatment market has been classified into hospitals, pharmacy, and others. Among them, the hospitals category grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period. Hospitals often have access to advanced diagnostic facilities and medical specialists, which can aid in accurately diagnosing pleurodynia. The ability to differentiate pleurodynia from other conditions with similar symptoms is crucial for providing appropriate treatment.
• For a better understanding of the market adoption of pleurodynia treatment, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), and Rest of World. North America, particularly the United States, is a hub for biotechnology and pharmaceutical research. In North America, including the United States and Canada, there has been a growing emphasis on rare diseases and orphan drugs. Pleurodynia, being a relatively rare condition, falls into this category. Governments, regulatory agencies, and healthcare organizations have recognized the need to address unmet medical needs for rare diseases and incentivize research and development of treatments. For instance, in 2020, Moderna Inc., a biotechnology company based in the United States, gained significant attention for its groundbreaking mRNA-based COVID-19 vaccine, which was authorized for emergency use during the COVID-19 pandemic. The success and prominence of Moderna in the field of mRNA-based vaccines have been instrumental in highlighting the potential of mRNA technology for various medical conditions, including rare diseases. Moreover, Advancements in medical technology have the potential to impact the treatment of various medical conditions, including pleurodynia. In the North America region, where healthcare infrastructure and funding for research are relatively robust, the adoption of cutting-edge technologies can lead to improved diagnostics, better monitoring of patients, and the development of innovative treatment options.
• Some of the major players operating in Eli Lilly, Bayer AG, Reckitt Benckiser plc, Bristol-Myers Squibb, Novartis, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals, Pfizer Inc., Merck among others. Several M&A’s along with partnerships have been undertaken.